- Home
- A-Z Publications
- Current Drug Delivery
- Previous Issues
- Volume 8, Issue 3, 2011
Current Drug Delivery - Volume 8, Issue 3, 2011
Volume 8, Issue 3, 2011
-
-
Editorial [Hot Topic: Nanotechnology Enables Superior Medical Therapies (Guest Editors: Marianna Foldvari & Mahmoud Elsabahy)]
Authors: Marianna Foldvari and Mahmoud ElsabahyNanomedicine is a new term, used to define the medical applications of nanotechnology. It encompasses the next era in drug delivery and diagnostics and imaging of health and disease conditions. This Special Issue is intended to bring to the forefront some major issues on regulatory challenges, examples for nanopharmaceutical product concepts based on nanoscale materials and evaluation of their safety or potentia Read More
-
-
-
Regulating Nanomedicine - Can the FDA Handle It?
By Raj BawaThere is enormous excitement and expectation surrounding the multidisciplinary field of nanomedicine - the application of nanotechnology to healthcare - which is already influencing the pharmaceutical industry. This is especially true in the design, formulation and delivery of therapeutics. Currently, nanomedicine is poised at a critical stage. However, regulatory guidance in this area is generally lacking and critically needed Read More
-
-
-
Non-Viral Nucleic Acid Delivery: Key Challenges and Future Directions
Authors: Mahmoud Elsabahy, Adil Nazarali and Marianna FoldvariGene therapy holds the promise of correcting a genetic defect. It can be achieved with the introduction of a normal wild-type transgene into specific cells of the patient where the endogenous gene is underexpressing or by the introduction of a therapeutic agent, such as, antisense oligonucleotides (AON) or small interfering RNA (siRNA) to inhibit transcription and/or translation of an overexpressing endogenous gene Read More
-
-
-
Nanomedicine: A New Frontier in Cancer Therapeutics
Authors: Pui Yan Lee and Kenneth K.Y. WongNanotechnology is a cutting edge and rapidly evolving technology in medicine. The potential of nanomedicine in cancer therapy is infinitely promising due to the fact that novel developments are constantly being explored. This is particularly the case in the use of nanoparticles in both tumor diagnosis, as well as treatment. This article will attempt to describe some recent advances using nanoparticle drug delivery syste Read More
-
-
-
Cancer, Signal Transduction and Nanotechnology
Authors: Poulomi Sengupta, Sudipta Basu and Shiladitya SenguptaUnderstanding the mechanisms underlying different cellular signaling pathways implicated in the pathogenesis of cancer are leading to the identification of novel drug targets as well as novel drug candidates. Multiple targeted therapeutics that modulate aberrant molecular pathways have already reached the clinic. However, targeted therapeutics can exert mechanism-driven side effects as a result of the implication Read More
-
-
-
Part I: Targeted Particles for Cancer Immunotherapy
Authors: Samar Hamdy, Azita Haddadi, Zahra Ghotbi, Ryan W. Hung and Afsaneh LavasanifarDendritic cells (DCs) are the key antigen presenting cells that link innate and adaptive immunity. In the periphery, DCs capture antigens, process them and migrate into the regional lymph nodes where they could initiate antigen specific T cell immune responses. Immunotherapeutic strategies that aim to deliver tumor antigens specifically to DCs could not only boost anti-tumor immune responses but also could alleviate non-spe Read More
-
-
-
Part II: Targeted Particles for Imaging of Anticancer Immune Responses
Authors: Ryan W. Hung, Samar Hamdy, Azita Haddadi, Zahra Ghotbi and Afsaneh LavasanifarThe interaction of dendritic cells (DCs) and T cells has been the cornerstone of approaches to cancer immunotherapy. Antitumoral immune responses can be elicited by delivering cancer antigens to DCs. As antigen presenting cells, these DCs activate cancer antigen specific T cells. Whereas the first part of the review discusses methods for delivery of cancer vaccines to DCs, in this part the focus is on the potential ro Read More
-
-
-
Peptide-Based Subunit Nanovaccines
Authors: Mariusz Skwarczynski and Istvan TothClassical vaccines incorporating live or attenuated microorganisms possess several disadvantages and cannot be applied against cancer and some pathogens. Modern vaccines utilizing immunogenic subunits derived from a particular pathogen are able to overcome these obstacles but need a specific delivery system for their efficacy. Nanotechnology has opened a new window into these delivery methodologies. A nano-sized fo Read More
-
-
-
CH50: A Revisited Hemolytic Complement Consumption Assay for Evaluation of Nanoparticles and Blood Plasma Protein Interaction
Authors: Ameena Meerasa, Jasper G. Huang and Frank X. GuThe use of nanoparticles as platforms or vehicles for applications in nanomedicine, such as drug delivery and medical imaging, has been widely reported in the literature. A key area of potential improvement in the development and implementation of nanoparticles is the design of surface treatments to maximize residence time in the bloodstream. Major obstacles to the prolonged circulation of nanoparticles include comple Read More
-
-
-
Amino Acid-Substituted Gemini Surfactant-Based Nanoparticles as Safe and Versatile Gene Delivery Agents
Authors: Jagbir Singh, Peng Yang, Deborah Michel, Ronald E. Verrall, Marianna Foldvari and Ildiko BadeaGene based therapy represents an important advance in the treatment of diseases that heretofore have had either no treatment or cure. To capitalize on the true potential of gene therapy, there is a need to develop better delivery systems that can protect these therapeutic biomolecules and deliver them safely to the target sites. Recently, we have designed and developed a series of novel amino acid-substituted gemini s Read More
-
-
-
Biphasic Vesicles for Topical Delivery of Interferon Alpha in Human Volunteers and Treatment of Patients with Human Papillomavirus Infections
Purpose: Topical biphasic vesicle delivery system encapsulating interferon alpha (IFN α) was developed as an alternative to injections used to treat human papillomavirus (HPV) infections. Methods: Biphasic lipid vesicles encapsulating increasing doses of IFN α (biphasic IFN α) were characterized for encapsulation efficiency, size, zeta potential and vesicle structure by centrifugation, dynamic light scattering, confocal microscopy a Read More
-
-
-
M Cells Prefer Archaeosomes: An In Vitro/In Vivo Snapshot Upon Oral Gavage in Rats
The archaeolipids (lipids extracted from archaebacterias) are non saponificable molecules that form self sealed mono or bilayers (archaeosomes-ARC). Different to liposomes with bilayers made of conventional glycerophospholipids, the bilayer of ARC posses a higher structural resistance to physico chemical and enzymatic degradation and surface hydrophobicity. In this work we have compared the binding capacity of ARC ex Read More
-
Volumes & issues
-
Volume 22 (2025)
-
Volume 21 (2024)
-
Volume 20 (2023)
-
Volume 19 (2022)
-
Volume 18 (2021)
-
Volume 17 (2020)
-
Volume 16 (2019)
-
Volume 15 (2018)
-
Volume 14 (2017)
-
Volume 13 (2016)
-
Volume 12 (2015)
-
Volume 11 (2014)
-
Volume 10 (2013)
-
Volume 9 (2012)
-
Volume 8 (2011)
-
Volume 7 (2010)
-
Volume 6 (2009)
-
Volume 5 (2008)
-
Volume 4 (2007)
-
Volume 3 (2006)
-
Volume 2 (2005)
-
Volume 1 (2004)
Most Read This Month
Article
content/journals/cdd
Journal
10
5
false
en

Most Cited Most Cited RSS feed
-
-
Preface
Authors: Deng-Guang Yu and He Lv
-
- More Less